Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.

Related Keywords

Italy ,Japan ,Riccardo Lencioni ,Department Of Surgery ,Critical Area Pathology ,Druvalumab And Bevacizumab Plus Tace ,Dotace ,Hcc ,Hepatocellular Carcinoma ,Gastrointestinal Cancer ,Gi Cancer ,Asco Gi ,Imfinzi ,Avastin ,Transarterial Chemoembolization ,Phase 3 Emerald 1 Trial ,Durvalumab ,Bevacizumab ,2024 Gastrointestinal Cancers Symposium ,D ,Università Di Pisa ,